EA201990360A1 - Аналоги амилина - Google Patents

Аналоги амилина

Info

Publication number
EA201990360A1
EA201990360A1 EA201990360A EA201990360A EA201990360A1 EA 201990360 A1 EA201990360 A1 EA 201990360A1 EA 201990360 A EA201990360 A EA 201990360A EA 201990360 A EA201990360 A EA 201990360A EA 201990360 A1 EA201990360 A1 EA 201990360A1
Authority
EA
Eurasian Patent Office
Prior art keywords
analogues
amilina
diseases
diabetes
disorders
Prior art date
Application number
EA201990360A
Other languages
English (en)
Inventor
Йеспер Мосольфф Матисен
Лисе Гим
Хенрик Кофод Мунк
Йеспер Скодборг Вилладсен
Дитер Вольфганг Хампрехт
Александр Хайм-Ритер
Джакомо Фоссати
Original Assignee
Зилэнд Фарма А/С
Бёрингер Ингельхайм Интернациональ Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Зилэнд Фарма А/С, Бёрингер Ингельхайм Интернациональ Гмбх filed Critical Зилэнд Фарма А/С
Publication of EA201990360A1 publication Critical patent/EA201990360A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)

Abstract

Настоящее изобретение относится к аналогам амилина и их применению для лечения или предотвращения ряда заболеваний, состояний или расстройств, включая ожирение, избыточное потребление пищи и связанные с ними метаболические заболевания, такие как диабет. Указанные аналоги обладают хорошей физической и химической стабильностью, хорошей растворимостью и большой продолжительностью действия и являются вполне подходящими для применения в форме жидкого состава.
EA201990360A 2016-09-09 2017-09-11 Аналоги амилина EA201990360A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16188024 2016-09-09
PCT/EP2017/072718 WO2018046719A1 (en) 2016-09-09 2017-09-11 Amylin analogues

Publications (1)

Publication Number Publication Date
EA201990360A1 true EA201990360A1 (ru) 2019-09-30

Family

ID=56990230

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201990360A EA201990360A1 (ru) 2016-09-09 2017-09-11 Аналоги амилина

Country Status (26)

Country Link
US (4) US10071140B2 (ru)
EP (2) EP3510044B1 (ru)
JP (1) JP7064103B2 (ru)
KR (1) KR102498393B1 (ru)
CN (1) CN109863168B (ru)
AR (1) AR109514A1 (ru)
AU (1) AU2017322277B2 (ru)
BR (1) BR112019004534A2 (ru)
CA (1) CA3035958A1 (ru)
CL (1) CL2019000575A1 (ru)
CO (1) CO2019002159A2 (ru)
DK (1) DK3510044T3 (ru)
EA (1) EA201990360A1 (ru)
ES (1) ES2901386T3 (ru)
IL (1) IL264864B2 (ru)
MA (1) MA46180A (ru)
MX (1) MX2019002599A (ru)
MY (1) MY197024A (ru)
PE (1) PE20190963A1 (ru)
PH (1) PH12019500474A1 (ru)
SA (1) SA519401239B1 (ru)
SG (1) SG11201901423XA (ru)
TW (1) TWI784968B (ru)
UA (1) UA123369C2 (ru)
WO (1) WO2018046719A1 (ru)
ZA (1) ZA201901253B (ru)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3271381B1 (en) 2015-03-18 2021-09-08 Zealand Pharma A/S Amylin analogues
TWI784968B (zh) * 2016-09-09 2022-12-01 丹麥商西蘭製藥公司 澱粉素類似物
CA3116023A1 (en) 2018-10-11 2020-04-16 Intarcia Therapeutics, Inc. Human amylin analog polypeptides and methods of use
JOP20220110A1 (ar) 2019-11-11 2023-01-30 Boehringer Ingelheim Int ناهضات مستقبل npy2
KR20230045088A (ko) 2020-08-07 2023-04-04 베링거 인겔하임 인터내셔날 게엠베하 가용성 npy2 수용체 작용제
WO2022248419A2 (en) 2021-05-22 2022-12-01 Adocia Compositions comprising short-acting hormones for treating or preventing obesity and pumps comprising said composition
EP4144362A1 (en) 2021-09-06 2023-03-08 Adocia Compositions comprising short-acting hormones for treating or preventing obesity and pumps comprising said composition
EP4129324A1 (en) 2021-08-02 2023-02-08 Adocia Compositions comprising at least an amylin receptor agonist and a glp-1 receptor agonist
TW202346323A (zh) 2022-02-07 2023-12-01 英商梅迪繆思有限公司 具有改善的生物穩定性的ｇｌｐ—１及升糖素雙重激動肽
WO2023227133A1 (zh) * 2022-05-27 2023-11-30 杭州先为达生物科技股份有限公司 人胰淀素类似物、其衍生物及用途
CA3240994A1 (en) 2022-05-30 2023-12-07 Zealand Pharma A/S Liquid formulations of amylin analogues
WO2024022465A1 (zh) * 2022-07-29 2024-02-01 杭州九源基因工程有限公司 一种人胰淀素多肽衍生物及其用途
WO2024061919A1 (en) 2022-09-19 2024-03-28 Zealand Pharma A/S Combination therapy

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5175146A (en) 1989-12-05 1992-12-29 Vical, Inc. Synthetic calcitonin peptides
US5234906A (en) 1991-01-10 1993-08-10 Amylin Pharmaceuticals, Inc. Hyperglycemic compositions
HU222249B1 (hu) 1991-03-08 2003-05-28 Amylin Pharmaceuticals Inc. Eljárás amilin agonista peptidszármazékok és ezeket tartalmazó gyógyszerkészítmények előállítására
DK0567626T3 (da) 1991-11-19 2001-12-17 Amylin Pharmaceuticals Inc Amylin-agonist-peptider og anvendelse deraf
EP0717635B1 (en) 1993-09-07 2000-11-15 Amylin Pharmaceuticals, Inc. Methods for regulating gastrointestinal motility
BRPI9711437B8 (pt) 1996-08-30 2021-05-25 Novo Nordisk As derivados de glp-1
DK0929567T3 (da) 1996-09-09 2005-06-27 Zealand Pharma As Forbedret fastfase-peptidsyntese og middel til anvendelse af en sådan syntese
US5677279A (en) 1996-12-16 1997-10-14 Amylin Pharmaceuticals, Inc. Methods and compositions for treating pain with amylin or agonists thereof
US7101853B2 (en) 1997-05-06 2006-09-05 Amylin Pharmaceuticals, Inc. Method for treating or preventing gastritis using amylin or amylin agonists
CA2206028C (en) 1997-06-04 2006-10-03 Frantisek Ziak Fitness-balance board
US7910548B2 (en) 1997-06-06 2011-03-22 Amylin Pharmaceuticals, Inc. Methods for treating obesity
WO1999034764A2 (en) 1998-01-09 1999-07-15 Amylin Pharmaceuticals, Inc. Amylin agonist pharmaceutical compositions containing insulin
US6451987B1 (en) 1999-03-15 2002-09-17 Novo Nordisk A/S Ion exchange chromatography of proteins and peptides
EP1956000B1 (en) 1999-03-17 2016-10-05 Novo Nordisk A/S Acylating agents useful for acylating peptides
WO2005000222A2 (en) 2003-05-30 2005-01-06 Amylin Pharmaceuticals, Inc. Novel methods and compositions for enhanced transmucosal delivery of peptides and proteins
JP2008500281A (ja) * 2004-02-11 2008-01-10 アミリン・ファーマシューティカルズ，インコーポレイテッド アミリンファミリーペプチドおよびそれらを作成し使用するための方法
WO2005077072A2 (en) 2004-02-11 2005-08-25 Amylin Pharmaceuticals, Inc. Hybrid polypeptides with selectable properties
DE102004051014A1 (de) 2004-10-20 2006-04-27 Rwth Aachen Chemisch modifizierte Peptidanaloga
AU2006279680B2 (en) 2005-08-11 2012-12-06 Amylin Pharmaceuticals, Llc Hybrid polypeptides with selectable properties
US8486890B2 (en) 2006-03-15 2013-07-16 Novo Nordisk A/S Amylin derivatives
KR20150116465A (ko) 2007-02-15 2015-10-15 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 글루카곤/ｇｌｐ-1 수용체 공동-항진물질
ATE520714T1 (de) 2007-06-15 2011-09-15 Zealand Pharma As Glucagonanaloga
EP2036539A1 (en) 2007-09-11 2009-03-18 Novo Nordisk A/S Stable formulations of amylin and its analogues
EP2036923A1 (en) 2007-09-11 2009-03-18 Novo Nordisk A/S Improved derivates of amylin
WO2010046357A1 (en) 2008-10-21 2010-04-29 Novo Nordisk A/S Amylin derivatives
ES2439499T3 (es) 2008-12-15 2014-01-23 Zealand Pharma A/S Análogos de glucagón
NZ593813A (en) 2008-12-15 2013-02-22 Zealand Pharma As Glucagon analogues
CA2747112A1 (en) 2008-12-15 2010-06-24 Zealand Pharma A/S Glucagon analogues
CN102282167B (zh) 2008-12-15 2014-08-13 西兰制药公司 胰高血糖素类似物
US8748375B2 (en) 2009-03-17 2014-06-10 Amylin Pharmaceuticals, Llc Methods for affecting body composition using amylin agonists
NZ597981A (en) 2009-07-13 2014-02-28 Zealand Pharma As Acylated glucagon analogues
EP2504355B1 (en) 2009-11-25 2015-07-22 Novo Nordisk A/S Method for making polypeptides
AR081975A1 (es) 2010-06-23 2012-10-31 Zealand Pharma As Analogos de glucagon
NZ604208A (en) 2010-06-24 2014-10-31 Zealand Pharma As Glucagon analogues
CN103596972B (zh) 2011-06-10 2018-03-20 诺沃—诺迪斯克有限公司 多肽
AP2014007797A0 (en) 2011-12-23 2014-07-31 Boehringer Ingelheim Int Glucagon analogues
US8575091B1 (en) 2012-04-19 2013-11-05 Novo Nordisk A/S Amylin analogues and pharmaceutical compositions thereof
WO2013156594A1 (en) 2012-04-19 2013-10-24 Novo Nordisk A/S Human amylin analogues
TWI608013B (zh) 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物
AR097701A1 (es) * 2013-09-19 2016-04-13 Zealand Pharma As Análogos de amilina
US9988429B2 (en) 2013-10-17 2018-06-05 Zealand Pharma A/S Glucagon analogues
MY176022A (en) 2013-10-17 2020-07-21 Boehringer Ingelheim Int Acylated glucagon analogues
DK3137494T3 (da) 2014-05-02 2021-10-04 Univ New York State Res Found Isletamyloidpolypeptider med forbedret opløselighed
CN106687474A (zh) 2014-09-04 2017-05-17 诺和诺德股份有限公司 新型胰淀素和降钙素受体激动剂
EP3271381B1 (en) * 2015-03-18 2021-09-08 Zealand Pharma A/S Amylin analogues
TWI784968B (zh) 2016-09-09 2022-12-01 丹麥商西蘭製藥公司 澱粉素類似物
WO2018144671A1 (en) 2017-02-01 2018-08-09 The Research Foundation For The State University Of New York Mutant islet amyloid polypeptides with improved solubility and methods for using the same

Also Published As

Publication number Publication date
PH12019500474A1 (en) 2019-08-05
MA46180A (fr) 2021-03-24
AU2017322277B2 (en) 2021-11-11
IL264864B2 (en) 2023-10-01
US20210346468A1 (en) 2021-11-11
CN109863168B (zh) 2023-04-18
US11382956B2 (en) 2022-07-12
MY197024A (en) 2023-05-22
KR20190045333A (ko) 2019-05-02
EP4074729A1 (en) 2022-10-19
WO2018046719A1 (en) 2018-03-15
US20200188485A1 (en) 2020-06-18
ES2901386T3 (es) 2022-03-22
CO2019002159A2 (es) 2019-07-31
EP3510044A1 (en) 2019-07-17
AU2017322277A1 (en) 2019-03-28
CA3035958A1 (en) 2018-03-15
AR109514A1 (es) 2018-12-19
EP3510044B1 (en) 2021-11-24
IL264864B1 (en) 2023-06-01
CL2019000575A1 (es) 2019-05-10
UA123369C2 (uk) 2021-03-24
CN109863168A (zh) 2019-06-07
BR112019004534A2 (pt) 2019-06-25
US20190134159A1 (en) 2019-05-09
JP2019534248A (ja) 2019-11-28
IL264864A (ru) 2019-04-30
US20180071366A1 (en) 2018-03-15
SA519401239B1 (ar) 2023-07-09
PE20190963A1 (es) 2019-07-08
DK3510044T3 (da) 2021-12-13
US10071140B2 (en) 2018-09-11
TW201811818A (zh) 2018-04-01
TWI784968B (zh) 2022-12-01
ZA201901253B (en) 2022-10-26
MX2019002599A (es) 2019-09-18
SG11201901423XA (en) 2019-03-28
JP7064103B2 (ja) 2022-05-10
KR102498393B1 (ko) 2023-02-13

Similar Documents

Publication Publication Date Title
EA201990360A1 (ru) Аналоги амилина
EA201791617A1 (ru) Аналоги амилина
PH12019550050A1 (en) Isoxazole analogs as fxr agonists and methods of use thereof
EA201792354A1 (ru) Композиции обетихолевой кислоты и способы применения
EA201790273A1 (ru) Флагеллиновые композиции и их применение
EA201890767A1 (ru) C4-модифицированные производные олеаноловой кислоты для ингибирования il-17 и других применений
EA201792562A1 (ru) Глюкагон и коагонисты гпп-1
EA201692177A1 (ru) Соединения и композиции в качестве агонистов toll-подобного рецептора 7
EA201691590A1 (ru) Бензимидазол-2-амины в качестве ингибиторов midhi
EA201491335A1 (ru) Бигуанидные композиции и способы лечения метаболических расстройств
EA201590058A1 (ru) Аналоги глюкагона
EA201591839A1 (ru) Терапевтические пептиды
EA201791348A1 (ru) Композиция орлистата и акарбозы с модифицированным высвобождением для лечения ожирения и связанных метаболических нарушений
EA201890449A1 (ru) Фумагиллиновые гетероциклические соединения и способы их получения и применения
EA201692049A1 (ru) Гетероарилзамещенные гетероциклилсульфоны
EA201790519A1 (ru) Терапевтические соединения в качестве ингибиторов рецептора орексина-1
EA201891727A1 (ru) Композиции на основе дейтерированного домперидона и способы терапии расстройств
EA202091020A1 (ru) Замещенные имидазопиридинамиды и их применение
EA201692008A1 (ru) Замещенные сконденсированные гетероциклы в качестве модуляторов gpr119 для лечения диабета, ожирения, дислипидемии и связанных нарушений
EA201791432A1 (ru) Композиции на основе пролекарства монометилфумарата
EA201791611A1 (ru) Лечение пациентов детского возраста с сахарным диабетом 2 типа с помощью ликсисенатида
EA201691792A1 (ru) Фармацевтические составы на основе вилдаглиптина
EA201691498A1 (ru) Новая мишень для лечения и профилактики диабета
EA201791154A1 (ru) Лечение болезней и нарушений аналогами кальцитонина
CO2020002500A2 (es) Análogos de insulina acilados novedosos y usos de estos